NVCR Stock Plummets 35% After Its Ovarian Cancer Treatment Fails

said Monday its electrical-based cancer treatment failed to make a difference for ovarian cancer patients. NVCR stock plummeted on the news. In afternoon trading on today's stock market, Novocure shares crashed 34.6% and traded near 19.50. The company tested its tumor-treating technology along…#novocure #wedbush #davidnierengarten #nierengarten #isi #vijaykumar #allisongatlin #twitter #ibdagatlin #novonordisk
Source: Reuters: Health - Category: Consumer Health News Source Type: news